ELVN · Enliven Therapeutics, Inc. · Stock research

Current Thesis

The June 11 EHA binary is behind the tape, and what emerges is a funded, best-in-class oral BCR::ABL1 inhibitor mid-transition to a pivotal with the sell-side racing to re-rate after the fact. ELVN-001 updated Phase 1 ENABLE efficacy/safety in previously-treated CML at an EHA 2026 oral on June 11; the next morning Enliven priced an upsized offering (8,933,334 shares at $37.50, pre-funded warrants at $37.499, ~$400M gross). Stacked on $462.6M cash at Dec 31 2025, pro-forma cash clears $800M and funds the asset through Phase 3 ENABLE-2 launch (guided 2H 2026). New since the raise: three price-target hikes in 14 days Jones Trading to $70 (6/29), Stifel to $80 (7/1, up from $60 on 6/9), HC Wainwright to $64 (7/9) against a $37.50 print. The catalyst that carried the run from ~$15 to a $48.53 high is spent; what remains is a de-risked compounder digesting ~17% dilution while analysts mark the model higher.

Bullish and bearish views on Enliven Therapeutics, Inc.

The model's bull view on Enliven Therapeutics, Inc. (ELVN), in brief: Competitive MMR in a harder line: 69% cumulative MMR by 24 weeks (26 evaluable, 60/120 mg) in previously-treated CML per the EHA 2026 abstract near asciminib's 67.7% MMR (ASC4FIRST, ASCO 2024-06) but in pretreated patients, not first line. The bear view: The catalyst is spent: EHA was the dominant near-term binary and it passed. Both cases follow in full.

Bull Case

• Competitive MMR in a harder line: 69% cumulative MMR by 24 weeks (26 evaluable, 60/120 mg) in previously-treated CML per the EHA 2026 abstract near asciminib's 67.7% MMR (ASC4FIRST, ASCO 2024-06) but in pretreated patients, not first line.
• Works after best-in-class fails: 52% cumulative MMR in asciminib-pretreated patients the commercial wedge for the population cycling off Scemblix with few remaining options.
• Tolerability is the pitch: no maximum tolerated dose and no new safety signals across 141 enrolled at ~32-week median treatment (EHA 2026). Ponatinib and asciminib carry arterial-occlusive/cardiovascular baggage; a clean profile is the share-capture argument.
• Over-funded balance sheet: $462.6M (Dec 31 2025) plus ~$400M gross from the 6/12 raise takes pro-forma cash above $800M, removing forced-secondary risk for years.
• Sell-side re-rate underway: Stifel to $80 (7/1) from $60 (6/9), Jones $70 (6/29), HC Wainwright $64 (7/9) a cluster of raises confirming the Phase 3 transition narrative post-event.
• Registrational step-up ahead: Phase 3 ENABLE-2 guided to initiate 2H 2026 after FDA dose alignment the structural upgrade from Phase 1 to a pivotal.

Bear Case

• The catalyst is spent: EHA was the dominant near-term binary and it passed. The abstract carried previously-reported numbers (47%/38% in the mature 80 mg cohort, 52% asciminib-pretreated), so June 11 was incremental follow-up, not a first-look surprise.
• Dilution just landed: 8,933,334 new shares plus pre-funded warrants is roughly a 17% larger count overhang the tape must absorb before the next leg.
• Buying after the re-rate: with PTs already $64–$80 against a $37.50 print, the easy sell-side catch-up is done, so the early-mover edge that this playbook hunts for has largely been priced.
• Cross-trial comparisons flatter: 69% is 24-week previously-treated among only 26 evaluable; asciminib's 67.7% is 1L at 48 weeks. Small denominators and different treatment lines make "beats Scemblix" fragile until a controlled Phase 3.
• Modest near-term TAM: US CML incidence runs ~8,500 cases/yr; absent 1L capture and ex-US expansion the revenue case sits in 2028+.
• Live competitor defense: Novartis protects the Scemblix franchise aggressively; next-gen asciminib or ASC4START-type data narrowing the tolerability gap blunts the core edge.

Setup & Price Structure

• The June 12 offering at $37.50 is the reference floor secondary buyers set cost there, so it separates "digesting" from "sell-the-news." A sustained hold above it keeps the funded-compounder read intact.
• The $48.53 pre-raise high is the overhead supply the stock must reclaim to signal the dilution has been absorbed and the move toward the $64–$80 target band is live.
• Deeper structural support sits near $16 (the 2024 post-secondary base); a break there would wipe the multi-quarter accumulation and marks the hard risk boundary no accumulation below it.
• Theme membership narrowed to oncology-immunology on 7/10 with the group flagged as accelerating, so the sector tape is a tailwind into any Phase 3 headline rather than a drag.

Catalyst Calendar (next 30 days)

• No dated binary inside the next 30 days. The June 11 EHA readout and June 12 financing are both complete.
• Phase 3 ENABLE-2 initiation guided 2H 2026 (no fixed date); FDA dose alignment is the gating step and a trial-start announcement is the next structural catalyst.
• Q2 2026 results est. ~mid-August 2026 (outside the 30-day window); a runway update with Phase 3 timing color rather than an efficacy event.
• Additional sell-side notes are plausible given the 6/29–7/9 cluster, though these mark the narrative rather than schedule a dated catalyst.

What Would Change Our Mind

• A weekly close below $37.50 puts every secondary buyer underwater and confirms the offering was absorbed as distribution rather than accumulation.
• Phase 3 ENABLE-2 failing to initiate within 2H 2026, or FDA non-alignment on the registrational dose, breaks the graduation-to-pivotal thesis.
• Any new Grade ≥3 arterial-occlusive/cardiovascular safety signal erases the tolerability wedge that is the entire differentiation.
• Novartis next-gen asciminib data (or a 1L ASC4START-type read) closing the tolerability gap commoditizes the edge and caps the share-capture case.

Correlation Notes

• Clinical-catalyst biotech: idiosyncratic on company data, but conference-day and thematic correlation with other precision-oncology names (KYMR, RLAY, CRNX) runs high (~0.8) into shared ASCO/EHA windows overlapping-conference exposure behaves as a single concentrated bet.
• Direct read-through to Novartis (NVS): competitive data cuts both ways a strong Scemblix update pressures ELVN, a tolerability stumble helps it.
• Beta to the broad biotech tape (XBI/IBB) plus the rate sensitivity typical of pre-revenue names; a tightening macro regime compresses long-duration biotech multiples regardless of asset quality.